Other options in the treatment of advanced breast cancer

Seminars in Oncology

Volumn 38, Issue SUPPL. 2, 2011, Pages

  Cobleigh, Melody A ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; METHOTREXATE; NAVELBINE; PACLITAXEL; PEMETREXED; TRASTUZUMAB EMTANSINE;

ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; BLOOD TOXICITY; BREAST CANCER; CANCER SURVIVAL; CONFERENCE PAPER; DIARRHEA; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG ERUPTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ERYTHROCYTE TRANSFUSION; FATIGUE; FEBRILE NEUTROPENIA; FEVER; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HUMAN; HYPOKALEMIA; INFLUENZA; LEUKOPENIA; LUNG EMBOLISM; LYMPHOCYTOPENIA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; DISEASE PROGRESSION; DRUGS, INVESTIGATIONAL; FEMALE; HUMANS;

EID: 79956210767     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2011.04.005     Document Type: Conference Paper

References (27)

1. Navelbine [package insert] 2007 Pierre Fabre Pharmaceuticals Inc Parsippany, NJ
2. M. Degardin, J. Bonneterre, and B. Hecquet Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer Ann Oncol 5 1994 423 426 (Pubitemid 24159646)
3. R.B. Livingston, G.K. Ellis, and J.R. Gralow Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer J Clin Oncol 15 1997 1395 1400 (Pubitemid 27167371)
4. Gemzar [package insert] 2010 Eli Lilly and Company Indianapolis, IN
5. M.R. Valerio, G. Cicero, and M. Armata Gemcitabine (G) in pretreated breast cancer [abstract 1953] Proc Am Soc Clin Oncol 20 2001 51b
6. S.Y. Rha, Y.H. Moon, and H.C. Jeung Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer Breast Cancer Res Treat 90 2005 215 221 (Pubitemid 40576834)
7. S. Modi, V.E. Currie, and A.D. Seidman A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane Clin Breast Cancer 6 2005 55 60 (Pubitemid 40872947)
8. J.L. Blum, M.A. Savin, and G. Edelman Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes Clin Breast Cancer 7 2007 850 856
9. A. Llombart-Cussac, M. Theodoulou, and K. Rowland Pemetrexed in patients with locally advanced or metastatic breast cancer who had received previous anthracycline and taxane treatment: phase II study Clin Breast Cancer 7 2006 380 385 (Pubitemid 46157558)
10. M. Martin, M. Spielmann, and M. Namer Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines Ann Oncol 14 2003 1246 1252 (Pubitemid 37039051)
11. J.A. O'Shaughnessy, R.S. Clark, and J.L. Blum Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer Clin Breast Cancer 6 2005 143 149 (Pubitemid 40975610)
12. Doxil [package insert] 2008 Ortho Biotech Products L.P Raritan, NJ
13. R.E. Coleman, L. Biganzoli, and P. Canney A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993) Eur J Cancer 542 2006 882 887
14. Camptosar [package insert] August 2010 Pfizer, Inc New York, NY
15. E.A. Perez, D.W. Hillman, and J.A. Mailliard Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both J Clin Oncol 22 2004 2849 2855 (Pubitemid 41079903)
16. I.E. Krop, M. Beeram, and S. Modi Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer J Clin Oncol 28 2010 2698 2704
17. Vogel C, Burris HA, Limentani S, et al. A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (MBC): Final results. Poster presented at: 45th Annual Meeting of the American Society of Clinical Oncology; 2009 May 29June 2; Orlando, FL.
18. NCT00829166 An open-label study of trastuzumab-MCC-DM1 (T-DM1) vs. capecitabine + lapatinib in patients with HER2-positive locally advanced or metastatic breast cancer (EMILIA) clinicaltrials.gov Accessed November 17, 2010
19. J. Fasano, and F. Muggia Breast cancer arising in a BRCA-mutated background: therapeutic implications from an animal model and drug development Ann Oncol 20 2009 609 614
20. B. Sirohi, M. Arnedos, and S. Popat Platinum-based chemotherapy in triple-negative breast cancer Ann Oncol 19 2008 1847 1852
21. T. Byrski, T. Huzarski, and R. Dent Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients Breast Cancer Res Treat 115 2009 359 363
22. T. Byrski, J. Gronwald, and T. Huzarski Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy J Clin Oncol 28 2010 375 379
23. D.P. Silver, A.L. Richardson, and A.C. Eklund Efficacy of neoadjuvant cisplatin in triple-negative breast cancer J Clin Oncol 28 2010 1145 1153
24. Gronwald J, Byrski T, Huzarski T, et al. Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Paper presented at the 45th Annual Meeting of the American Society of Clinical Oncology; 2009 May 29-June 2; Orlando, FL.
25. NCT00483223 Platinum for triple-negative metastatic breast cancer and evaluation of p63/p73 as a biomarker of response www. clinicaltrials.gov Accessed November 17, 2010
26. NCT00532727 Triple negative breast cancer trial (TNT) www. clinicaltrials.gov Accessed November 17, 2010
27. NCT00861705 Paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide in treating patients with breast cancer that can be removed by surgery www.clinicaltrials.gov Accessed November 17, 2010